CD274 and nonpapillary renal cell carcinoma: Over the past decade, checkpoint inhibitor immunotherapies, targeting key T-cell modulators like PD-1, PD-L1, and CTLA-4, have demonstrated profound efficacy in ccRCC, both as monotherapies and combination regimens [20,21].